Biotech Values

[DewDiligence]

Oops by Hal Barron (Roche’s CMO and head of drug development):

The key issue here is not that because I think we’re all clear, it raises HDL by 30%, is that HDL functional. We know with pertuzumab it appeared not to be functional, there was no benefit. In fact there was toxicity. This is just a description of how we’re developing it. We’re focusing on a very high risk population. We’ve got this dalcetrapib trial which is event driven. The first interim has past and there was no safety concern, which was helpful to know, given what happen with Tofacitnib.

LOL—perhaps this is a transcription error.